EVALUATING THE ECONOMIC IMPACT OF ADOPTING SELINEXOR-BASED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN QATAR
Author(s)
Anas Hamad, MSc, PhD1, Ahmed AbdelMohsen, PharmD2, Pratik Ramesh Dhopte, MPH3, Rita Ojeil, MASc4.
1Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation; College of Pharmacy, QU Health Sector, Qatar University, Doha, Qatar, 2Menarini Stemline, Dubai, United Arab Emirates, 3Carexso, Dubai, United Arab Emirates, 4PDC-CRO, Dubai, United Arab Emirates.
1Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation; College of Pharmacy, QU Health Sector, Qatar University, Doha, Qatar, 2Menarini Stemline, Dubai, United Arab Emirates, 3Carexso, Dubai, United Arab Emirates, 4PDC-CRO, Dubai, United Arab Emirates.
OBJECTIVES: RRMM poses significant clinical and economic challenges. Selinexor, a first-in-class oral exportin-1 inhibitor with a unique mechanism of action, received regulatory approval based on the phase 3 BOSTON trial showing significantly improved progression-free survival, overall response, and clinically improved overall survival in combination with bortezomib+dexamethasone (SVd) versus Vd alone in RRMM (Grosicki. Lancet 2020). In Qatar, RRMM treatment relies on established therapies, with limited options for disease failing multiple lines of therapy. Switching drug class to selinexor offers an opportunity to improve outcomes while addressing financial implications.
METHODS: To assess the budgetary impact of introducing selinexor into the Qatar health system RRMM treatment landscape, a budget impact model was developed using available data on key inputs (eg, population, treatment and complication costs, adverse events [AEs]). Current standard-of-care (SOC) regimens were daratumumab[D]-carfilzomib-d, D-pomalidomide[P]-d, Pd. Total costs of current SOC for scenarios ±selinexor were estimated over a 5-year horizon. AE costs were estimated using microcosting.
RESULTS: Introducing SVd in Qatar is projected to generate substantial cost savings versus SOC. Over 5-years, SVd as second-line therapy reduces costs by QAR 472,630, primarily driven by lower drug (-QAR 153,300) and subsequent therapy costs (-QAR 329,443), offsetting slight increases in administration (+QAR 1,357) and disease state (+QAR 21,966) costs. The most significant drug cost reduction occurs in the first year, highlighting early economic impact. Using SVd in third-line results in savings of QAR 237,763, mainly due to reductions in drug and subsequent therapy costs, without additional administration or disease state expenditures.
CONCLUSIONS: This model shows that introducing SVd for RRMM in Qatar is cost-saving versus current SOC, reducing costs over 5 years primarily through lower drug and subsequent therapy expenses while optimizing downstream treatment requirements. Reductions in subsequent therapy costs are largely attributable to documented efficacy and improved outcomes of selinexor in RRMM patients.
METHODS: To assess the budgetary impact of introducing selinexor into the Qatar health system RRMM treatment landscape, a budget impact model was developed using available data on key inputs (eg, population, treatment and complication costs, adverse events [AEs]). Current standard-of-care (SOC) regimens were daratumumab[D]-carfilzomib-d, D-pomalidomide[P]-d, Pd. Total costs of current SOC for scenarios ±selinexor were estimated over a 5-year horizon. AE costs were estimated using microcosting.
RESULTS: Introducing SVd in Qatar is projected to generate substantial cost savings versus SOC. Over 5-years, SVd as second-line therapy reduces costs by QAR 472,630, primarily driven by lower drug (-QAR 153,300) and subsequent therapy costs (-QAR 329,443), offsetting slight increases in administration (+QAR 1,357) and disease state (+QAR 21,966) costs. The most significant drug cost reduction occurs in the first year, highlighting early economic impact. Using SVd in third-line results in savings of QAR 237,763, mainly due to reductions in drug and subsequent therapy costs, without additional administration or disease state expenditures.
CONCLUSIONS: This model shows that introducing SVd for RRMM in Qatar is cost-saving versus current SOC, reducing costs over 5 years primarily through lower drug and subsequent therapy expenses while optimizing downstream treatment requirements. Reductions in subsequent therapy costs are largely attributable to documented efficacy and improved outcomes of selinexor in RRMM patients.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE516
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology